10x Genomics/$TXG
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About 10x Genomics
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
Ticker
$TXG
Sector
Primary listing
Industry
Life Sciences Tools and Services
Headquarters
Employees
1,306
Website
10x Genomics Metrics
BasicAdvanced
$1.7B
-
-$1.30
1.94
-
Price and volume
Market cap
$1.7B
Beta
1.94
52-week high
$23.67
52-week low
$6.78
Average daily volume
3.8M
Financial strength
Current ratio
5.373
Quick ratio
4.444
Long term debt to equity
9.992
Total debt to equity
11.328
Interest coverage (TTM)
-60,529.67%
Profitability
EBITDA (TTM)
-143.834
Gross margin (TTM)
68.41%
Net profit margin (TTM)
-25.14%
Operating margin (TTM)
-28.73%
Effective tax rate (TTM)
-2.37%
Revenue per employee (TTM)
$480,000
Management effectiveness
Return on assets (TTM)
-12.43%
Return on equity (TTM)
-22.03%
Valuation
Price to revenue (TTM)
2.739
Price to book
2.46
Price to tangible book (TTM)
2.52
Price to free cash flow (TTM)
38.565
Free cash flow yield (TTM)
2.59%
Free cash flow per share (TTM)
36.59%
Growth
Revenue change (TTM)
-0.13%
Earnings per share change (TTM)
-42.13%
3-year revenue growth (CAGR)
7.76%
3-year earnings per share growth (CAGR)
17.44%
What the Analysts think about 10x Genomics
Analyst ratings (Buy, Hold, Sell) for 10x Genomics stock.
Bulls say / Bears say
10x Genomics' recent launch of Chromium Xo, a low-cost instrument for high-performance single-cell research, aims to expand access and potentially increase market share. (lifesciencereport.com)
The company's collaboration with the Chan Zuckerberg Initiative on the Billion Cells Project positions it at the forefront of AI-driven biological research, potentially leading to significant advancements and partnerships. (stockanalysis.com)
Despite recent challenges, 10x Genomics reported a 9.8% revenue growth, indicating resilience and the ability to expand its market reach. (directorstalkinterviews.com)
The acquisition of Fluent BioSciences by Illumina introduces a cost-effective competitor in the single-cell analysis market, potentially impacting 10x Genomics' Chromium product line. (markets.businessinsider.com)
Analysts have expressed concerns over the company's ability to sustain growth acceleration with its core products, beyond the incremental contribution from Xenium. (markets.businessinsider.com)
The current challenging macroeconomic climate presents a significant threat to 10x Genomics' business model, as research institutions and pharmaceutical companies may face budget constraints or reduced funding. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
10x Genomics Financial Performance
Revenues and expenses
10x Genomics Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for 10x Genomics stock?
10x Genomics (TXG) has a market cap of $1.7B as of July 28, 2025.
What is the P/E ratio for 10x Genomics stock?
The price to earnings (P/E) ratio for 10x Genomics (TXG) stock is 0 as of July 28, 2025.
Does 10x Genomics stock pay dividends?
No, 10x Genomics (TXG) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next 10x Genomics dividend payment date?
10x Genomics (TXG) stock does not pay dividends to its shareholders.
What is the beta indicator for 10x Genomics?
10x Genomics (TXG) has a beta rating of 1.94. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.